Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographic, tumor, and treatment characteristics by race/ethnicity

From: Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study

Variable Categories Total NHW AA HW P 1
N % N % N % N %
Total   366 100 58 16 73 20 235 64  
Age (years) < 50 95 26 18 31 19 26 58 25 0.613
≥ 50 271 74 40 69 54 74 177 75  
Mean (SD) 56.0 (9.1) 55.6 (9.1) 54.9 (9.2) 56.5 (9.1)  
BMI (kg/m2) < 25 96 26 29 50 12 16 55 23 < 0.0001
25–29.9 124 34 16 28 17 23 91 39  
≥ 30 146 40 13 22 44 60 89 38  
Mean (SD) 29.3 (6.4) 26.6 (6.3) 32.6 (8.4) 28.9 (5.2)  
Smoking status Never 240 66 37 64 51 70 152 64 0.490
Former 107 29 20 34 17 23 70 30  
Current 19 5 1 2 5 7 13 6  
Sum of 12 comorbid conditions2 0 147 40 28 48 19 26 100 43 0.119
1 137 37 20 34 32 44 85 36  
2 60 16 7 12 18 25 35 15  
≥ 3 22 6 3 5 4 5 15 6  
Tumor stage 0 74 20 7 12 14 19 53 23 0.003
IA-B 180 49 37 64 28 38 115 49  
IIA-B 90 25 13 22 29 40 48 20  
IIIA-C 22 6 1 2 2 3 19 8  
ER Positive 279 76 43 74 49 67 187 80 0.072
Negative 86 23 15 26 24 33 47 20  
PR Positive 243 66 36 62 44 60 163 69 0.243
Negative 122 33 22 38 29 40 71 30  
HER2 Positive 31 8 4 7 6 8 21 9 0.730
Negative 275 75 50 86 56 77 169 72  
Triple negative No 294 80 47 81 52 71 195 83 0.005
Yes 54 15 8 14 20 27 26 11  
Axillary surgery None/SLNB 248 68 39 67 54 74 155 66 0.439
ALND 118 32 19 33 19 26 80 34  
Chemotherapy No 195 53 31 53 39 53 125 53 0.999
Yes 171 47 27 47 34 47 110 47  
Hormone therapy/initiation time None/after RT 178 49 37 64 41 56 100 43 0.015
Aromatase inhibitor before RT 98 27 9 16 14 19 75 32  
Aromatase inhibitor during RT 14 4 3 5 2 3 9 4  
Tamoxifen before RT 64 17 6 10 12 16 46 20  
Tamoxifen during RT 12 3 3 5 4 5 5 2  
RT fractionation Conventional 306 84 45 78 64 88 197 84 0.298
Hypo 60 16 13 22 9 12 38 16  
Total RT dose (Gy) < 60 107 29 21 36 18 25 68 29 0.348
≥ 60 259 71 37 64 55 75 167 71  
Mean (SD) 58.2 (4.8) 58.4 (4.6) 58.7 (4.9) 58.0 (4.8)  
Boost Yes 331 90 56 97 65 89 210 89 0.225
No 35 10 2 3 8 11 25 11  
Breast volume (cc) < 892.1 (median) 183 50 38 66 20 27 125 53 < 0.001
≥ 892.1 (median) 179 49 20 34 52 71 107 46  
Mean (SD) 996 (532) 799 (464) 1254 (645) 965 (479)  
Pre-RT pain Mean (SD) 1.7 (2.1) 1.0 (1.3) 2.0 (2.5) 1.8 (2.1) 0.023
Post-RT pain Mean (SD) 2.8 (2.5) 1.9 (1.7) 3.2 (2.6) 2.8 (2.6) 0.013
  1. 1P values from the chi-square test or Fisher's exact test, or ANOVA, excluding missing. Significant findings are in italics
  2. 2Sum of 12 patient-reported comorbid conditions: diabetes, hypertension, heart disease, lung disease, thyroid disease, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, and 2 others
  3. Abbreviations: NHW non-Hispanic whites, AA black or African American, HW Hispanic whites, SD standard deviation, BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, RT radiotherapy
Back to article page